Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel
Israeli regulatory approval is already in place, and Microbot anticipates initial distributor orders in the fourth quarter of 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Microbot Medical (MBOT) signed a three-year exclusive agreement with Medtechnica to market and sell its LIBERTY robotic system in Israel.
The system received regulatory approval from the Israeli Ministry of Health's AMAR Division and was registered in the Israeli Medical Device Registry in May 2026. Microbot anticipates initial orders under the agreement during the fourth quarter of 2026. The company also expects to enter additional markets and add distribution partners as it scales operations and expands manufacturing capacity. LIBERTY is FDA-cleared for peripheral endovascular procedures.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThree-year exclusive distribution agreement signed with Medtechnica to market and sell LIBERTY throughout Israel.
- Minor pointIsraeli regulatory approval and AMAR registration received in May 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Initial Medtechnica orders anticipated by Microbot during the fourth quarter of 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional markets and distribution partners anticipated by Microbot as it scales operations and expands manufacturing capacity.
Negative
- None.
Details
Market move: MBOT +3.27% vs previous close. Three-year Israel distribution agreement
On Oct 6, the day this news came out, the latest delayed price for MBOT is 3.27% above the previous close. Argus tracked a peak move of +3.6% during the session. Our momentum scanner has recorded 13 alerts for this stock so far that day. The latest delayed price is $1.10. Relative volume is exceptionally heavy at 7.4x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Agreement term
- 3 years
- Exclusive commercial distribution in Israel
- Israeli regulatory approval
- May 2026
- AMAR approval and registration in the Israeli Medical Device Registry
- Initial orders
- Q4 2026
- Anticipated under the distribution agreement
Historical Context
-
Reported Israeli marketing clearance, establishing regulatory access before this distribution agreement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
endovascular medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel
Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S.
HINGHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has signed a three-year exclusive commercial distribution agreement with Medtechnica Ltd. to market and sell the Company's LIBERTY System in Israel. The Company received regulatory approval from the Israeli Ministry of Health's AMAR Division, the authority responsible for medical device regulation in Israel, and was registered in the Israeli Medical Device Registry (AMAR) in May 2026. The Company anticipates initial orders from Medtechnica Ltd. under the agreement during the fourth quarter of 2026.
“We are excited to partner with Medtechnica Ltd., whose market expertise in the endovascular space and reputation make them an ideal partner to bring LIBERTY to physicians and patients throughout Israel,” commented Harel Gadot, CEO, President and Chairman. “This is an important milestone for us and is expected to lead to hospitals and physicians in Israel gaining access to the LIBERTY System and achieving the same positive experiences our U.S.-based customers are enjoying. Looking ahead, we anticipate entering new markets and adding further strategic distribution partners as we continue to scale our operations, expand our manufacturing capacity, and position Microbot to meet growing demand across both U.S. and international markets.”
“We are proud to partner with Microbot Medical and bring the LIBERTY Endovascular Robotic System to the Israeli endovascular market,” said Ravit Kremer, CEO of Medtechnica Ltd. “This agreement reflects Medtechnica’s ongoing commitment to introducing innovative medical technologies that can support physicians, advance clinical practice and improve patient care. With our strong presence and experience in the endovascular field, we look forward to working closely with Microbot Medical to introduce LIBERTY to leading hospitals and clinical teams across Israel.”
LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements pertaining to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Microbot Medical's distribution agreement with Medtechnica cover?
The three-year exclusive commercial distribution agreement authorizes Medtechnica to market and sell Microbot Medical's LIBERTY Endovascular Robotic System throughout Israel.
When does Microbot Medical expect initial orders from Medtechnica?
Microbot Medical anticipates initial orders from Medtechnica under the agreement during the fourth quarter of 2026.